Department of Urogynaecology, 3rd Floor, Golden Jubilee Wing, Kings College Hospital, London, UK.
Maturitas. 2010 Apr;65(4):340-7. doi: 10.1016/j.maturitas.2009.12.022. Epub 2010 Jan 22.
Urinary incontinence remains a common and distressing condition affecting many women and is known to have a significant effect on quality of life (QoL). Whilst conservative and behavioural therapy are important in the management of women with both stress incontinence and overactive bladder (OAB) ultimately many may benefit from pharmacological therapy. Antimuscarinic drugs are the commonly used agents in the treatment of OAB although often compliance and persistence are affected by adverse effects. Consequently many newer agents remain under investigation. In addition duloxetine has recently been introduced for the management of women with stress incontinence and may offer an alternative to surgery in selected cases. The aim of this review is to provide an overview of the current and new developments in the management of women with urinary incontinence as well as reviewing the role of oestrogen therapy in relation to lower urinary tract dysfunction.
尿失禁仍然是一种常见且令人痛苦的疾病，影响着许多女性，已知对生活质量（QoL）有重大影响。虽然保守治疗和行为疗法在治疗压力性尿失禁和膀胱过度活动症（OAB）患者中很重要，但最终许多患者可能受益于药物治疗。抗胆碱能药物是治疗 OAB 的常用药物，但由于不良反应，通常会影响依从性和持久性。因此，许多新的药物仍在研究中。此外，度洛西汀最近被引入用于治疗压力性尿失禁的女性，在某些情况下可能替代手术。本综述的目的是概述女性尿失禁管理的现状和新进展，并回顾雌激素治疗在与下尿路功能障碍相关方面的作用。
